Peg MGF 5mg/vial 1 Vial by Bio-Peptide

Usage

1. Calculate your target dose in mcg and determine the corresponding volume based on your reconstitution concentration (e.g., 200 mcg from a 2.5 mg/ml solution = 0.08 ml).
2. Wipe the vial rubber stopper with an alcohol swab and allow it to dry for 10 seconds before needle insertion.
3. Draw the calculated volume into a 29–31 gauge insulin syringe, tapping gently to displace any air bubbles before expelling them.
4. Select a subcutaneous injection site — abdomen or upper thigh — and clean the skin with a fresh alcohol swab; rotate sites across sessions.
5. Administer the injection within 30–60 minutes after completing a resistance training session, as this window aligns with peak satellite-cell responsiveness to mechanical-overload signalling.
6. Cap the used syringe immediately, dispose via a sharps container, and return the reconstituted vial to refrigeration at 2–8 °C; log the date of each administration to track within the 28-day use-by window.

Warnings

Frequently asked questions

What exactly is Mechano Growth Factor and how does it differ from IGF-1?

Mechano Growth Factor (MGF) is a splice variant of IGF-1 that the body generates locally within mechanically stressed muscle tissue — not a systemic hormone, but a locally expressed repair signal. Its E-domain peptide sequence differs from standard IGF-1, giving it a distinct receptor-binding profile focused on satellite cell recruitment rather than general anabolic signalling. In short: MGF is exercise-triggered, localised, and repair-specific, whereas IGF-1 is systemically circulating and broadly anabolic.

How long after a workout should PEG-MGF be injected for optimal satellite cell activation?

Most research protocols position PEG-MGF injection within 30–60 minutes post-training, the window during which mechanical overload signalling is at its peak and satellite cells are transitioning from quiescence toward activation. Because PEG-MGF's half-life extends to 48–96 hours, a single post-workout injection can sustain receptor engagement well into the multi-day recovery period, covering repair phases that a rapidly degrading native MGF molecule would miss entirely.

What does PEGylation do to the MGF peptide and why does it matter?

PEGylation attaches polyethylene glycol chains to the MGF peptide backbone, physically blocking proteolytic enzymes from cleaving the sequence in plasma. The result is a half-life extension from roughly 2–5 minutes (native MGF) to approximately 48–96 hours (PEG-MGF), verified in pharmacokinetic studies on PEGylated peptides. This matters because it converts a locally acting, rapidly cleared molecule into a systemically distributed repair signal capable of reaching satellite cells in muscle groups beyond the directly trained area.

How do you reconstitute and store the Bio-Peptide PEG-MGF 5mg vial?

Reconstitute the lyophilised powder by injecting bacteriostatic water slowly down the vial wall — avoid vortexing or shaking, which can denature the peptide. A common reconstitution volume is 1–2ml, producing a 2.5–5mg/ml solution. Store the sealed lyophilised vial at 2–8 °C refrigerated, or at −20 °C for long-term archival. Once reconstituted, keep the solution refrigerated at 2–8 °C and use within 28 days; do not freeze a reconstituted solution.

What syringe type is recommended for injecting reconstituted PEG-MGF?

Insulin syringes (29–31 gauge, 0.3–1ml capacity) are standard for subcutaneous PEG-MGF administration because they allow precise micro-volume dosing and minimise injection site trauma. Draw the calculated dose slowly, expel air bubbles by gently tapping the barrel, and inject subcutaneously into the abdominal or upper-thigh region. Rotate injection sites across sessions to prevent localised irritation or lipodystrophy from repeated puncture at the same site. (2) angle_used

Manufacturer

Bio-Peptide's entry into the research-peptide market was structured around a principle its founders chose to encode directly into the production release sequence — not as a compliance gesture, but as the literal criterion that determines whether a batch exists commercially at all: two independently sourced laboratory analyses must be completed and documented before a vial can carry the Bio-Peptide name. For PEG-MGF specifically — a chemically modified peptide where PEGylation chemistry introduces additional structural variables beyond the raw amino acid sequence — that two-step framework carries particular weight. The first analysis is HPLC (High-Performance Liquid Chromatography), contracted to a third-party laboratory and tasked with resolving the peptide's molecular architecture against reference standards to confirm both sequence fidelity and acceptable purity. The second is a LAL (Limulus Amebocyte Lysate) endotoxin assay, which detects gram-negative bacterial contamination at a sensitivity level appropriate for injectable research compounds. Both tests generate batch-specific documentation that accompanies the product record — a paper trail that is not optional or selective but structural to Bio-Peptide's release criteria. That constraint was built into the company before it reached any meaningful market scale, which means it predates the commercial incentives that might otherwise have encouraged shortcuts.